본문 바로가기

Josamycin suppresses Prevotella intermedia lipopolysaccharide-induced production of nitric oxide and interleukin-1 beta in murine macrophages

Josamycin suppresses Prevotella intermedia lipopolysaccharide-induced production of nitric oxide and interleukin-1β in murine macrophages

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q2Scopus Q3
저널
BIOMEDICINE & PHARMACOTHERAPY105 · pp.498 · 2018
피인용
Web of Science 6Scopus 5
FWCI (Scopus)
0.1
JCR IF
JCR 2017 3.457
ISSN
0753-3322

저자

  1. 최은영제1저자Department of Biological Science, College of Medical and Life Sciences, Silla University, Busan, South Korea
  2. Choe, So-HuiDepartment of Biological Science, College of Medical and Life Sciences, Silla University, Busan, South Korea
  3. 현진이Department of Biological Science, College of Medical and Life Sciences, Silla University, Busan, South Korea
  4. 박혜련Department of Oral Pathology, School of Dentistry, Pusan National University, Yangsan, South Korea
  5. Choi, In SoonDepartment of Biological Science, College of Medical and Life Sciences, Silla University, Busan, South Korea
  6. 김성조교신저자Department of Periodontology, School of Dentistry, Pusan National University, Yangsan, South Korea

초록

Aims: Josamycin has immunomodulatory properties independent of its antibacterial actions. This study was designed to explore the influences and associated mechanisms of josamycin upon the generation of proinflammatory mediators in murine macrophages activated with lipopolysaccharide (LPS) from Prevotella intermedia, a pathogenic bacterium associated with periodontal disease. Main methods: LPS was purified by employing phenol-water extraction protocol. Culture supernatants were analyzed for nitric oxide (NO) and interleukin (IL)-1 beta. Real-time PCR and immunoblotting were conducted to quantify mRNA and protein expression, respectively. The expression levels of IL-1 beta were analyzed by confocal laser scanning microscopy. NE-kappa B-dependent SEAP levels were estimated by reporter assay. Key findings: Josamycin significantly attenuated NO production elicited by P. intermedia LPS as well as induction of iNOS protein and mRNA in RAW264.7 cells. While the release of IL-1 beta from cells stimulated by LPS was suppressed in the presence of josamycin, josamycin failed to reduce the degree of IL-1 beta mRNA expression. Josamycin did not reduce the stability of IL-1 beta mRNA induced by P. intermedia LPS, M the same time josamycin also failed to suppress the LPS-induced intracellular IL-1 beta expression. Josamycin augmented HO-1 induction in cells exposed to P. intermedia LPS, and SnPP, an inhibitor of HO-1 activity, reversed the suppressive impact of josamycin upon NO generation induced by LPS. Josamycin diminished NE-kappa B transcriptional activity induced by P. intermedia LPS. Further, josamycin enhanced SOCS1 mRNA level in cells activated with LPS. Significance: Josamycin suppressed P. intermedia LPS-induced generation of NO and IL-1 beta in RAW264.7 macrophages via the inhibition of NF-kappa B activation as well as HO-1 and SOCS1 induction. Josamycin may have benefits as a host modulatory agent in treating periodontal disease.

키워드

josamycinnitric oxideinterleukin-1 betaHO-1NF-kappa BSOCS1LIPOPOLYSACCHARIDE-INDUCED PRODUCTIONNECROSIS-FACTOR-ALPHANF-KAPPA-BGINGIVAL CREVICULAR FLUIDCYTOKINE SIGNALING SOCSMACROLIDE ANTIBIOTICSPERIODONTAL-DISEASEIN-VITROPROINFLAMMATORY MEDIATORSSTIMULATES RELEASE

식별자

Scopus EID
2-s2.0-85047895394
WoS UID
000438312600055